Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 20 November 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1745867

Correction: TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study

This article is a correction to:

  1. Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC

    1. Read original article
Linan Yin&#x;Linan Yin1†Weihang Li&#x;Weihang Li1†Wencheng ShaoWencheng Shao2Xunbo HouXunbo Hou1Bowen LiuBowen Liu1Xuesong LiuXuesong Liu1Ruibao Liu*Ruibao Liu1*Peng Huang*Peng Huang3*
  • 1Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China
  • 2Department of Radiation Physics, Harbin Medical University Cancer Hospital, Harbin, China
  • 3Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China

A Correction on
TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study

By Yin L, Li W, Shao W, Hou X, Liu B, Liu X, Liu R and Huang P (2025) Front. Immunol. 16:1669856. doi: 10.3389/fimmu.2025.1669856

Author “Peng Huang” was erroneously assigned as corresponding author. The correct corresponding author is “Peng Huang and Ruibao Liu”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, Donafenib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, immune checkpoint inhibitors

Citation: Yin L, Li W, Shao W, Hou X, Liu B, Liu X, Liu R and Huang P (2025) Correction: TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study. Front. Immunol. 16:1745867. doi: 10.3389/fimmu.2025.1745867

Received: 13 November 2025; Accepted: 14 November 2025;
Published: 20 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Yin, Li, Shao, Hou, Liu, Liu, Liu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ruibao Liu, TGl1X3J1aWJhb0BzaW5hLmNvbQ==; Peng Huang, aHVhbmdwZW5nMjAwMiYjeDIwMTM7QDE2My5jb20=

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.